Novartis Home

Novartis scientists in the lab

At Novartis, we are reimagining medicine

Alcon becomes a separately traded standalone company

On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

Read more

Visualizing immuno-oncology research

Learn how Novartis researchers are working to outsmart tumors.

Read more

Cell & Gene Therapy at Novartis

Our teams aim to deliver on the promise of cell and gene therapy for patients.

Read more